GeneFerm Biotechnology Co., Ltd. (TPEX:1796)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Biotechnology	681.13M	523.08M	796.93M	635.65M	528.89M
Revenue from Internal Divisions	-4.03M	-1.92M	-3.16M	-1.68M	-6.55M
Total	677.10M	521.16M	793.77M	633.96M	522.33M

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Taiwan	433.44M	370.03M	499.22M	525.90M	406.97M
United States	141.22M	79.47M	220.44M	63.44M	70.71M
China	27.00M	33.10M	31.11M	25.41M	27.43M
Others	75.44M	38.55M	43.00M	19.22M	17.23M
Total	677.10M	521.16M	793.77M	633.96M	522.33M

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 28, 2026

Data Sources Report a data error